Bluejay Diagnostics (BJDX)
Develops near-patient IL-6 diagnostics for sepsis risk assessment.
Something off on this page? Send us feedback.
Develops the Symphony analyzer and single-use cartridges for near-patient IL-6 testing in critical-care settings, with a planned model centered on recurring cartridge sales. The pre-revenue business is concentrated on an investigational sepsis-risk test that requires FDA authorization before U.S. diagnostic marketing.
Develops the Symphony near-patient diagnostic platform: a compact analyzer and single-use cartridges designed to quantify interleukin-6 from whole blood for sepsis risk assessment in critical-care settings. Its sole active lead test is being developed for ICU patients with sepsis or septic shock.
Coordinates clinical and regulatory development from Massachusetts while Sanyoseiko in Japan supplies analyzers and cartridges, and Argonaut supports U.S. cartridge manufacturing, assembly and distribution. The planned model pairs a lower upfront analyzer outlay with recurring sales of single-use cartridges to hospitals, emergency rooms, intensive-care units and long-term acute-care facilities.
Remains pre-revenue, with a sole operating segment, a sole active platform and no cleared product. U.S. diagnostic marketing depends on FDA authorization, clinical validation, cartridge verification and quality manufacturing, while cartridge technology is licensed from Toray.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $9.6M · Total debt $80.7K · Total assets $11.5M · Shareholders' equity $9.4M
- Revenue
- $0
- Operating income
- −$2.3M
- Net income
- −$2.3M
No dividends on record.
| Institutions6 holders · as of Mar 31, 2026 | 5.69% | 58.8K shares | |
| Insiders5 holders · as of Aug 18, 2026 | 8.76% | 90.7K shares | |
| Strategic holders2 holders · as of Jul 22, 2026 | 8.90% | 92.1K shares | |
| Otherremainder | 76.65% | 793.2K shares |
1.03M company shares as of Aug 25, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (4.47M in the company's Sep 3, 2026 report, 1.03M elsewhere); stakes use the report.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Ayrton Capital LLCInstitution | 10.41% | 107,722 | 13Gfiled Aug 13, 2026 ↗ |
HRT Financial LPStrategic10 percent owner | 8.90% | 92,055 | Form 4filed Jul 13, 2026 ↗ |
Indranil DeyInsiderdirector, officer: President and CEO | 3.92% | 40,522 | Form 4filed Aug 18, 2026 ↗ |
Sabby Management, LLCInstitution | 2.78% | 28,726 | 13Fas of Mar 31, 2026 |
Geode Capital Management, LLCInstitution | 2.72% | 28,127 | 13Fas of Mar 31, 2026 |
| See all 23 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 10, 2026 | HRT Financial LP | 10 percent owner | −34,938 | $1.40 |
| Jul 9, 2026 | HRT Financial LP | 10 percent owner | +64,047 | $1.51 |
| Mar 14, 2026 | Svetlana Dey | director | +12,500 | $2.00 |
| Mar 14, 2026 | Fred S. Zeidman | director | +12,500 | $2.00 |
| Mar 14, 2026 | Donald R. Chase | director | +12,500 | $2.00 |
